省廣集團(002400.SZ):省廣營銷擬投設參股公司上海巨兆奎星數字科技
格隆匯7月23日丨省廣集團(002400.SZ)公佈,公司於2024年7月23日召開的第六屆董事會第十二次會議審議通過了《關於全資子公司擬投資設立參股公司的議案》,同意公司全資子公司省廣營銷集團有限公司(以下簡稱“省廣營銷”)與天下英才(北京)文化傳媒有限公司(以下簡稱“天下英才”)、深圳景玶澧源文化有限公司(以下簡稱“景玶澧源”)及珠海吉門打開科技有限公司(以下簡稱“吉門打開”)共同投資設立上海巨兆奎星數字科技有限公司(暫定名,最終以工商行政管理部門核准登記的名稱為準,以下簡稱“目標公司”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.